<DOC>
	<DOCNO>NCT02330250</DOCNO>
	<brief_summary>This project aim improve adherence rate pharmaceutical care patient systemic lupus erythematosus ( SLE ) help achieve therapeutic goal finally improve quality life patient .</brief_summary>
	<brief_title>Effectiveness Pharmaceutical Care Adherence Systemic Lupus Erythematosus Treatment</brief_title>
	<detailed_description>Adherence treatment primary determinant effectiveness health care . Non-compliance may lead therapeutic failure , make difficult complex management chronic disease cause death . The effectiveness intervention adherence important impact health population . Systemic lupus erythematosus ( SLE ) autoimmune disease high proportion hospital admission deaths high cost treatment . The prevalence adherence group patient Brazil low ( 31.7 % ) drug treatment complex . Our aim ass effectiveness Pharmaceutical Care adherence drug treatment SLE patient attend Rheumatology outpatient clinic Rio de Janeiro , Brazil . Randomized clinical trial ( pragmatic trial ) , 120 adult patient confirm SLE diagnosis follow 12 month , randomize two group : intervention group ( attended pharmacist accord Dader Method Pharmaceutical Care ) , control group ( attend non-pharmacist professional counseling hygiene/nutrition reduction risk lupus therapy ) . The main outcome adherence drug therapy secondary outcome improvement medical condition quality life patient .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Inclusion criterion : SLE diagnosis accord 2012 SLICC ( Systemic Lupus International Collaborating Clinics Group ) SLE classification criterion . Treatment corticosteroids antimalarial . History biopsyproven lupus nephritis class III , IV , V ( 2003 International Society Nephrology / Renal Pathology Society ) nephritic/nephrotic lupus flare undergone kidney biopsy . Current renal replacement therapy . Renal transplantation . Ongoing pulse therapy cyclophosphamide and/or methylprednisolone . Aid caregiver . Any psychiatric illness . Inability understand question questionnaire . Patients ` unwillingness sign inform consent .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Pharmaceutical care</keyword>
	<keyword>Pharmaceutical service</keyword>
	<keyword>Medication adherence</keyword>
</DOC>